Press Enter to search · ESC to close

AI × Crypto

AR1001 Alzheimer’s Phase III Topline Data to Debut at CTAD 2026

Topline results from the global pivotal Phase III POLARIS-AD trial of AR1001, an oral Alzheimer’s disease drug licensed by Fosun Pharma on a regional basis with exclusive options in core global markets, will be presented for the first time as an oral presentation at the 19th Clinical Trials on Alzheimer’s Disease conference (CTAD 2026) in Boston from November 16 to 19. The data will be disclosed on November 16.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback